Full Press Release Details
Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors.
DYN
Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors
Key Takeaway: Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+65%
120-day peak, hindsight
Typical move
13%
average across 7 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
Zeleciment Rostudirsen
Phase 3 · Duchenne Muscular Dystrophy (DMD)